In a deal valued at more than $660 million, Baring Private Equity Asia showed up Monday as the buyer of a Japanese CMO and Tokio Marine Capital as the seller.
With Actavis and Allergan's deal agreement, the Botox maker is getting what it's wanted for months--a way to thwart hostile bidder Valeant. And Actavis? It's getting a glimpse of a future that holds $23 billion in annual revenue, and that would officially punch its ticket into Big Pharma.
Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.
Catalent has acquired another R&D tech firm, snapping up Micron Technologies and its particle sizing capabilities as the recently IPO'd company works to expand its share of the drug development market.
A months-long pursuit of Allergan may be about to come to a close for Valeant and activist investor Bill Ackman--but not with the results they were hoping for.
Actavis and Allergan have come to terms on a buyout that values the Botox maker at $66 billion, dwarfing a bid from Valeant and William Ackman that forced the biotech into play. And it gives Actavis CEO Brent Saunders exactly what he's been looking for: Bragging rights to top 10 status in the Big Pharma world--after brushing aside a weakening Eli Lilly.
With Pfizer's eligibility to bid again for AstraZeneca nearing, the drug giant seems unlikely to make another run at its one-time target, industry-watchers say. But that doesn't mean it isn't prepping a run at someone else.
AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.
Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan--and word is it could happen quickly.
Ex-Apple CEO John Sculley sees the mobile health market as the future patient-preferred healthcare option